Dan W Haupt

Summary

Affiliation: Washington University School of Medicine
Country: USA

Publications

  1. ncbi Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Am J Psychiatry 166:345-53. 2009
  2. ncbi Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    Neuropsychopharmacology 32:2561-9. 2007
  3. ncbi Plasma leptin and adiposity during antipsychotic treatment of schizophrenia
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Neuropsychopharmacology 30:184-91. 2005
  4. ncbi Differential metabolic effects of antipsychotic treatments
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    Eur Neuropsychopharmacol 16:S149-55. 2006
  5. ncbi The metabolic effects of antipsychotic medications
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Can J Psychiatry 51:480-91. 2006
  6. ncbi Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110 1093, USA
    Arch Gen Psychiatry 59:337-45. 2002
  7. ncbi Abnormalities in glucose regulation associated with mental illness and treatment
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110-1093, USA
    J Psychosom Res 53:925-33. 2002
  8. ncbi Impact of medical comorbidity on medication management of schizophrenia
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA
    CNS Spectr 12:15-7. 2007
  9. ncbi Metabolic risks and effects of atypical antipsychotic treatment
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 68:e24. 2007
  10. ncbi Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia
    Daniel E Casey
    J Clin Psychiatry 65:4-18; quiz 19-20. 2004

Detail Information

Publications11

  1. ncbi Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Am J Psychiatry 166:345-53. 2009
    ....
  2. ncbi Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    Neuropsychopharmacology 32:2561-9. 2007
    ..Adiposity levels occurring during antipsychotic treatment are strongly related to insulin resistance, confirming that antipsychotic-induced weight gain can contribute to increased cardiometabolic risk in this population...
  3. ncbi Plasma leptin and adiposity during antipsychotic treatment of schizophrenia
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110 1093, USA
    Neuropsychopharmacology 30:184-91. 2005
    ..The results argue against a role for defective leptin secretion or sensitivity in the weight gain induced by antipsychotic medications...
  4. ncbi Differential metabolic effects of antipsychotic treatments
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO 63110, USA
    Eur Neuropsychopharmacol 16:S149-55. 2006
    ..This differential risk highlights the need for adequate monitoring in patients receiving treatment with second-generation antipsychotics and careful selection of treatment in high-risk patients...
  5. ncbi The metabolic effects of antipsychotic medications
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, St Louis, Missouri 63110, USA
    Can J Psychiatry 51:480-91. 2006
    ....
  6. ncbi Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia
    John W Newcomer
    Department of Psychiatry, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110 1093, USA
    Arch Gen Psychiatry 59:337-45. 2002
    ..While antipsychotics may increase adiposity, which can decrease insulin sensitivity, disease- and medication-related differences in glucose regulation might also occur independent of differences in adiposity...
  7. ncbi Abnormalities in glucose regulation associated with mental illness and treatment
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, 660 S Euclid, St Louis, MO 63110-1093, USA
    J Psychosom Res 53:925-33. 2002
  8. ncbi Impact of medical comorbidity on medication management of schizophrenia
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA
    CNS Spectr 12:15-7. 2007
  9. ncbi Metabolic risks and effects of atypical antipsychotic treatment
    Dan W Haupt
    Department of Psychiatry, Washington University School of Medicine, St Louis, MO, USA
    J Clin Psychiatry 68:e24. 2007
    ..The physician should also address patient lifestyle issues such as a poor diet and lack of exercise...
  10. ncbi Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia
    Daniel E Casey
    J Clin Psychiatry 65:4-18; quiz 19-20. 2004
  11. ncbi Perceptions of weight gain and bipolar pharmacotherapy: results of a 2005 survey of physicians in clinical practice
    Terence A Ketter
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California 94305 5723, USA
    Curr Med Res Opin 22:2345-53. 2006
    ..To assess the perceptions of clinicians in the psychiatric community about pharmacotherapy and its impact on weight gain and adverse metabolic effects in patients with bipolar disorder...